These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16230419)
1. Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity. Acres B; Gantzer M; Remy C; Futin N; Accart N; Chaloin O; Hoebeke J; Balloul JM; Paul S Cancer Res; 2005 Oct; 65(20):9536-46. PubMed ID: 16230419 [TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621 [TBL] [Abstract][Full Text] [Related]
4. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
6. [Anti-tumor effects induced by fusion of interleukin-18 gene transfected NCI-H460 lung cancer cell line with dendritic cells]. Zhang ZY; Wu JM Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):17-20. PubMed ID: 17575687 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Mueller K; Schweier O; Pircher H Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743 [TBL] [Abstract][Full Text] [Related]
9. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198 [TBL] [Abstract][Full Text] [Related]
10. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. Gillies SD; Lan Y; Wesolowski JS; Qian X; Reisfeld RA; Holden S; Super M; Lo KM J Immunol; 1998 Jun; 160(12):6195-203. PubMed ID: 9637539 [TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189 [TBL] [Abstract][Full Text] [Related]
12. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related]
13. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293 [TBL] [Abstract][Full Text] [Related]
14. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900 [TBL] [Abstract][Full Text] [Related]
15. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. Pillet AH; Bugault F; Thèze J; Chakrabarti LA; Rose T J Immunol; 2009 May; 182(10):6267-77. PubMed ID: 19414780 [TBL] [Abstract][Full Text] [Related]
17. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Bachmann MF; Wolint P; Walton S; Schwarz K; Oxenius A Eur J Immunol; 2007 Jun; 37(6):1502-12. PubMed ID: 17492805 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218 [TBL] [Abstract][Full Text] [Related]
19. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]